01/02/2018 11:30:00

Vical and Mycoses Study Group Education and Research Consortium Establish Collaboration to Advance Vical’s Novel Antifungal VL-2397 for the Treatment of Invasive Aspergillosis

SAN DIEGO, Feb. 01, 2018 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) and the Mycoses Study Group Education and Research Consortium (MSGERC) today announced the establishment of a collaboration to advance Vical’s novel antifungal drug product candidate for the treatment of invasive aspergillosis. This collaboration will combine the clinical development expertise of Vical with the specialized expertise of the MSGERC in the area of invasive fungal infections.

“We are excited to establish this collaboration with the world’s leading mycology clinicians and thought leaders,” said Dr. Mammen “Anza” Mammen, Vical’s Senior Vice President, Clinical Development. “We believe the MSGERC will add substantial value to our VL-2397 antifungal program by serving as advisors to our Phase 2 trial and helping provide exposure for the study among their member clinicians who may be interested in taking part as investigators.”

The U.S. Food and Drug Administration (FDA) has advised that VL‑2397 would be eligible for a Limited Use Indication (LUI) approval assuming a successful outcome of a single Phase 2 trial carried out in accordance with a protocol and statistical analysis plan consistent with the Agency's advice. The final determination whether the drug is approvable will be made by FDA after review of all relevant data.

The LUI is a provision of the Limited Population Pathway established under the 21st Century Cures Act of 2016. Vical plans to initiate a single Phase 2 trial for the treatment of invasive aspergillosis in acute leukemia patients and allogeneic hematopoietic cell transplant (HCT) recipients in the first quarter of 2018.

About VL-2397

VL-2397 is Vical’s novel antifungal compound that was licensed from Astellas Pharma in 2015. VL-2397 was isolated from a leaf litter fungus collected in a Malaysian national park and represents the first agent in a potentially new class of antifungal drugs. The FDA has granted Vical Qualified Infectious Disease Product (QIDP), Orphan Drug and Fast Track designations for VL-2397 in the treatment of invasive aspergillosis.

About Invasive Aspergillosis

Invasive aspergillosis is a life-threatening infection that typically affects immunocompromised patients, including those with acute leukemia and recipients of allogeneic HCT or lung transplants. Infection typically starts in the lungs and rapidly disseminates to other tissues. More than 200,000 cases of invasive aspergillosis are diagnosed annually worldwide.

About Vical

Vical develops biopharmaceutical products for the prevention and treatment of chronic or life-threatening infectious diseases, including antiviral and antifungal candidates in clinical development. Additional information on Vical is available at www.vical.com.


The Mycoses Study Group Education & Research Consortium is a non-profit organization dedicated to providing continuing medical education and scientific/medical thought leadership for evidence-based medicine in the diagnoses, prevention, treatment and maintenance of patients at risk for or afflicted with invasive fungal infections. This organization will also serve as a resource and support for patients and caregivers who are affected by these serious rare diseases. This group’s mission includes setting the annual educational and research agendas for mycology and providing top-quality continuing education initiatives to MSG-member institutions and to other institutions and practitioners throughout the United States and globally.

Forward-Looking Statements

This press release contains forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward-looking statements include anticipated developments in clinical programs, including the plans, timing of initiation, and enrollment for clinical trials, and expected benefits of the collaboration between Vical and MSGERC. Risks and uncertainties include whether Vical or others will continue development of  VL-2397; the risk that the collaboration between Vical and MSGERC is terminated earlier than expected or does not result in expected benefits to the development of VL-2397; the risk that the FDA does not grant LUI approval of VL-2397 following the results of Vical’s planned Phase 2 clinical trial; whether Vical will be able to obtain regulatory allowances or guidance necessary to proceed with proposed clinical trials or implement anticipated clinical trial designs; whether on-going or planned clinical trials will be initiated or completed on the timelines Vical currently expects; whether any product candidates will be shown to be safe and efficacious in clinical trials; the fact that results from the planned Phase 2 clinical trial of VL-2397 may be inconsistent with the results from prior preclinical studies and clinical trials; whether Vical will have access to sufficient capital to fund its planned development activities; whether Vical will seek or gain approval to market any product candidates; and additional risks set forth in the Company's filings with the Securities and Exchange Commission. These forward-looking statements represent the Company's judgment as of the date of this release. The Company disclaims, however, any intent or obligation to update these forward-looking statements.


Andrew Hopkins

(858) 646-1127

Website:  www.vical.com

Primary Logo

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
22 Mar
Hejsa   I aftes var der igen nyt fra Conferenceboard omkring de ledende indikatorer. Der er ti param..
22 Mar
Trumps yderst vigtige og største begrundelse for sanktionerne mod Kina, er at Kina og kineserne uden..
22 Mar
Hej alle,   Jeg har jo meldt ud at jeg har solgt stort set alle mine aktier og sidder 2018 over (not..
18 Mar
https://invst.ly/6yhto   På candelstik chartet med den ugentlige tidsramme, har bulls købt på begge ..
22 Mar
Med al respekt, vil du ikke være venlig at holde din kæft omkring det forpulede "krak" snak.
19 Mar
Værdiansættelse/kursmål ligger lige omkring 300 for samtlige bankernes eksperter. Lau Svendsen blev ..
21 Mar
The plan includes the construction of the 522-megawatt Sagamore Wind Project in New Mexico, which in..
19 Mar
  Flere studier har allerede dokumenteret Envarsus er det immunsuppressiv præparater, anholdende Tac..
23 Mar
Roland.. Du er meget snart på vej væk fra dette forum. Måske du kan fornemme det og det er derfor du..
23 Mar
Kongsmart og 6212 var endt på et skummelt morgenværtshus en meget tidlig morgen. Som altid når de va..

HSBC Bank Plc : Form 8.5 (EPT/RI) - Lonmin PLC

22/02/2018 10:54:53

Rathbone Brothers Plc : Preliminary announcement of 2017 results

22/02/2018 07:00:19
Funds under management up 14.3% to £39.1 billionThis is a preliminary statement of annual results published in accordance with FCA Listing Rule 9.7A. It covers the year ended 31 December 2017. Mark Nicholls, Chairman of Rathbone Brothers Plc, said: "UK and global investment markets performed well in 2017, with some indices reaching record levels towards the end of the year. This outcome has b..

Elliott Capital Advisors, L.P : Form 8.3 - GKN Plc

21/02/2018 15:25:10
FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the "Code") 1.         KEY INFORMATION (a) Full name of discloser: Elliott Capital Advisors, L.P. (for itself and related general partners ..

Most read news

  • 24 hours
  • 48 hours
  • 1 week
High Tech Algae Farming Industry Gets Boost with Introduction of Bipartisan Algae Agriculture Act of 2018
Long Blockchain Corp. Announces Minority Investment in TSLC, a Singapore-Based Financial Technology Company with a Strategic Ownership Position in CASHe
Marijuana-Related MJ Munchies, Subsidiary of NightFood (NGTF), Developing Half-Baked Snack Line With Leading Food Science Firm
BIMobject AB: BIMobject releases toolkit to help digitalise the construction industry
Auryn Resources Announces Closing of US$9.8 Million Financing

Buy and sell signals

  • Trend
  • Moneymachine

Latest news

Copyright Euroinvestor A/S 2018   Disclaimer and Terms of Use
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
24 March 2018 07:55:05
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20180321.2 - EUROWEB6 - 2018-03-24 08:55:05 - 2018-03-24 07:55:05 - 1000 - Website: OKAY